Cocrystal Pharma Receives HREC Approval To Initiate Phase 1 Study To Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma has received approval from the Human Research Ethics Committee (HREC) to initiate a Phase 1 study for its oral broad-spectrum coronavirus 3CL protease inhibitor, CDI-988. This marks a significant step in the development of a potential treatment for COVID-19.
May 31, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cocrystal Pharma's HREC approval to initiate a Phase 1 study for CDI-988 could positively impact the company's stock price in the short term.
The HREC approval is a significant milestone for Cocrystal Pharma, as it allows the company to proceed with the development of a potential COVID-19 treatment. This news could attract investor interest and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100